Badanie skuteczności MaaT013 w leczeniu ostrej choroby przeszczep przeciwko gospodarzowi (aGvHD) przewodu pokarmowego u pacjentów opornych na ruxolitinib

Acute graft-versus-host disease, often referred to as aGVHD, is a condition that can occur after a stem cell or bone marrow transplant. It happens when the donated cells attack the recipient's body, particularly affecting the gastrointestinal tract. This study focuses on patients with aGVHD who have not responded well to a medication called ruxolitinib. The purpose of the study is to evaluate the effectiveness of a new treatment called MaaT013, which is a rectal solution containing pooled allogeneic fecal microbiota. This treatment aims to help patients who are resistant or intolerant to ruxolitinib.

The study will involve administering MaaT013 to participants and observing their response over a period of time. The main goal is to see how well the treatment works in improving the condition of the gastrointestinal tract by day 28. Participants will receive the treatment rectally, and their progress will be monitored to assess the overall response rate. The study will also look at the safety of MaaT013 and its effects on other organs, as well as the duration of the response and overall survival rates.

Throughout the study, researchers will collect data to understand how MaaT013 affects patients with aGVHD. This includes measuring the response of the gastrointestinal tract and other organs, as well as tracking any changes in the patients' health and quality of life. The study aims to provide valuable information on the potential benefits of MaaT013 for patients who have limited treatment options due to resistance or intolerance to existing therapies.